BACK
TO MAIN
PAGE

Ebola

General Information

Ebola virus disease is a rare but severe, often fatal illness in humans.​

Vaccines to protect against Ebola have been developed and have been used to help control the spread of Ebola outbreaks in Guinea and in the Democratic Republic of the Congo (DRC).​

Two monoclonal antibodies were approved for the treatment of Zaire ebolavirus infection in adults and children by the US Food and Drug Administration in late 2020.​

Transmission

The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.

Show More

Epidemiology

The average fatality rate is around 50% (varying from 25% to 90% in past outbreaks).​

2016

To date, the largest reported outbreak of Ebola virus disease occurred in the three West African countries from 2014 through 2016, with over 28,000 cases and 11,000 deaths ​

Vaccines
Pipeline

2
Vaccines in
the pipeline

Technology Platforms

  • Glycoconjugate vaccine (1)
  • Viral vector (1)

DEVELOPMENT PHASES

  • Phase I (1)
  • Under Regulatory Review (1)

TRIAL POPULATION

    Paediatric + Adults (1)​
    Adults (1)​

Source: 
https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
https://www.ecdc.europa.eu/en/infectious-disease-topics/z-disease-list/ebola-virus-disease/facts/factsheet-about-ebola-virus
[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review